Tag - ATAI

Developments

atai and Beckley to combine establishing market leader in psychedelic mental health therapies

atai Life Sciences (NASDAQ: ATAI) and closely held Beckley Psytech announced a definitive agreement to combine in an all-share transaction subject to Phase 2b success criteria of BPl-003 in patients with treatment...

June 2, 2025

Developments

atai unit initiates Phase 1 trial for MDMA derivative EMP-01

EmpathBio, a unit of atai Life Sciences (NASDAQ:ATAI), received regulatory and ethics approval to begin enrollment of its Phase 1 study of EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment...

September 28, 2022

Developments

atai Life Sciences prices $225-million IPO

atai Life Sciences (NASDAQ:ATAI) priced an initial public offering of 15 million common shares at $15 each for gross proceeds of $225-million. In its first day of trading on June 18, the stock jumped $4.45, or 29%, to...

June 18, 2021

Tag - ATAI

atai and Beckley to combine establishing market leader in psychedelic mental health therapies

atai unit initiates Phase 1 trial for MDMA derivative EMP-01

atai Life Sciences prices $225-million IPO

Subscribe